Hikma Pharmaceuticals (LON:HIK) Shares Down 14.1% Following Analyst Downgrade

Hikma Pharmaceuticals PLC (LON:HIK)’s share price traded down 14.1% during mid-day trading on Thursday after Berenberg Bank lowered their price target on the stock from GBX 2,510 to GBX 2,300. Berenberg Bank currently has a buy rating on the stock. Hikma Pharmaceuticals traded as low as GBX 1,522 and last traded at GBX 1,522. 166,325,172 shares were traded during trading, an increase of 7,989% from the average session volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

A number of other research analysts also recently commented on HIK. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a research note on Friday. Peel Hunt reiterated a “buy” rating and issued a GBX 2,170 price target on shares of Hikma Pharmaceuticals in a report on Friday. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Finally, JPMorgan Chase & Co. reduced their target price on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating on the stock in a report on Friday. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Hikma Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of GBX 2,416.

Insider Transactions at Hikma Pharmaceuticals

In other news, insider Laura Balan Balan acquired 3,500 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were bought at an average price of GBX 1,821 per share, for a total transaction of £63,735. Also, insider Mazen Darwazah purchased 315,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were purchased at an average cost of GBX 1,601 per share, with a total value of £5,043,150. In the last 90 days, insiders have acquired 332,500 shares of company stock worth $533,130,500. 17.77% of the stock is currently owned by insiders.

Hikma Pharmaceuticals Stock Performance

The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.82. The firm has a market capitalization of £3.50 billion, a price-to-earnings ratio of 9.47, a price-to-earnings-growth ratio of 2.38 and a beta of 0.41. The company has a 50-day moving average of GBX 1,730.88 and a 200-day moving average of GBX 1,893.97.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.